Literature DB >> 10435641

Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET.

E Vigna1, D Gramaglia, P Longati, A Bardelli, P M Comoglio.   

Abstract

TPR-MET, a transforming counterpart of the c-MET proto-oncogene detected in experimental and human cancer, results from fusion of the MET kinase domain with a dimerization motif encoded by TPR. In this rearrangement the exons encoding the Met extracellular, transmembrane and juxtamembrane domains are lost. The juxtamembrane domain has been suggested to be a regulatory region endowed with negative feedback control. To understand whether its absence is critical for the generation of the Tpr-Met transforming potential, we produced a chimeric molecule (Tpr-juxtaMet) with a conserved juxtamembrane domain. The presence of the domain (aa 962-1009) strongly inhibited Tpr-Met dependent cell transformation. Cell proliferation, anchorage-independent growth, motility and invasion were also impaired. The enzymatic behavior of Tpr-Met and Tpr-juxtaMet was the same, while Tpr-juxtaMet ability to associate cytoplasmic signal transducers and to elicit downstream signaling was severely impaired. These data indicate that the presence of the juxtamembrane domain counterbalances the Tpr-Met transforming potential and therefore the loss of the exon encoding the juxtamembrane domain is crucial in the generation of the active TPR-MET oncogene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435641     DOI: 10.1038/sj.onc.1202791

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  19 in total

1.  CD44 is required for two consecutive steps in HGF/c-Met signaling.

Authors:  Véronique Orian-Rousseau; Linfeng Chen; Jonathan P Sleeman; Peter Herrlich; Helmut Ponta
Journal:  Genes Dev       Date:  2002-12-01       Impact factor: 11.361

2.  Proapoptotic function of the MET tyrosine kinase receptor through caspase cleavage.

Authors:  David Tulasne; Julien Deheuninck; Filipe Calheiros Lourenco; Fabienne Lamballe; Zongling Ji; Catherine Leroy; Emilie Puchois; Anice Moumen; Flavio Maina; Patrick Mehlen; Véronique Fafeur
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

3.  Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.

Authors:  Weiru Wang; Adhirai Marimuthu; James Tsai; Abhinav Kumar; Heike I Krupka; Chao Zhang; Ben Powell; Yoshihisa Suzuki; Hoa Nguyen; Maryam Tabrizizad; Catherine Luu; Brian L West
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-28       Impact factor: 11.205

4.  LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy.

Authors:  David L Shattuck; Jamie K Miller; Melanie Laederich; Melanie Funes; Heidi Petersen; Kermit L Carraway; Colleen Sweeney
Journal:  Mol Cell Biol       Date:  2006-12-18       Impact factor: 4.272

5.  c-MET as a potential therapeutic target and biomarker in cancer.

Authors:  J Rafael Sierra; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

6.  MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.

Authors:  Xinyuan Lu; Nir Peled; John Greer; Wei Wu; Peter Choi; Alice H Berger; Sergio Wong; Kuang-Yu Jen; Youngho Seo; Byron Hann; Angela Brooks; Matthew Meyerson; Eric A Collisson
Journal:  Cancer Res       Date:  2017-05-18       Impact factor: 12.701

7.  A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3'-kinase activation and endothelial cell migration.

Authors:  H Gille; J Kowalski; L Yu; H Chen; M T Pisabarro; T Davis-Smyth; N Ferrara
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

Review 8.  The multiple paths towards MET receptor addiction in cancer.

Authors:  Leslie Duplaquet; Zoulika Kherrouche; Simon Baldacci; Philippe Jamme; Alexis B Cortot; Marie-Christine Copin; David Tulasne
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

Review 9.  Molecular mechanisms of SH2- and PTB-domain-containing proteins in receptor tyrosine kinase signaling.

Authors:  Melany J Wagner; Melissa M Stacey; Bernard A Liu; Tony Pawson
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

10.  The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.

Authors:  Rosa Marina Melillo; Anna Maria Cirafici; Valentina De Falco; Marie Bellantoni; Gennaro Chiappetta; Alfredo Fusco; Francesca Carlomagno; Antonella Picascia; Donatella Tramontano; Giovanni Tallini; Massimo Santoro
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.